Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
GlobeNewswire Inc.
3 hours ago
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LI
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
GlobeNewswire Inc.
3 hours ago
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary an
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
GlobeNewswire Inc.
5 hours ago
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, an
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
GlobeNewswire Inc.
7 hours ago
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants ag
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewswire Inc.
7 hours ago
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-20
Searchless.ai Launches as the First Publication Dedicated to Covering the End of Traditional Search
Newsfile
11 hours ago
New daily intelligence publication tracks the shift from Google to AI-powered discovery as 56% of searches now end without a clickRome, Italy--(Newsfile Corp. - March 28, 2026) - Searchless.ai has launched as a new publication focused on exclusively
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
GlobeNewswire Inc.
12 hours ago
Rocket Lab Electron Launch For European Space Agency Rocket Lab Electron Launch For European Space Agency MAHIA, New Zealand, March 28, 2026 (GLOBE NEWSWIRE) -- Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in
McLaren Resources Completes Financing
Newsfile
20 hours ago
Toronto, Ontario--(Newsfile Corp. - March 27, 2026) - McLaren Resources Inc. (CSE: MCL) (FSE: 3ML) ("McLaren" / the "Company") announces final closing of a non-brokered private placement financing. McLaren has raised gross total proceeds of $662,500.
CopAur Minerals to Provide a Kinsley Mountain Update on the Emerging Growth Conference on April 2nd, 3:40 - 3:50 pm Eastern Time
Newsfile
21 hours ago
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - Andrew Neale, CEO of CopAur Minerals Inc. (TSXV: CPAU) (the "Company") invites individual and institutional investors as well as advisors and analysts, to attend the Company's real-time
Spin.AI Named Winner of the Coveted Global InfoSec Awards During RSAC Conference 2026
Newsfile
22 hours ago
San Francisco, California--(Newsfile Corp. - March 27, 2026) - Spin.AI is honored to announce that it has been recognized as a winner of five awards from Cyber Defense Magazine (CDM), the industry's leading electronic information security magazine, a

